WAVE Life Sciences Ltd. (WVE) to Release Quarterly Earnings on Monday
WAVE Life Sciences Ltd. (NASDAQ:WVE) is set to announce its earnings results on Monday, August 14th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.
WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Wednesday, May 10th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.12. The firm had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.80 million. WAVE Life Sciences had a negative return on equity of 48.16% and a negative net margin of 3,172.14%. On average, analysts expect WAVE Life Sciences to post $-3.31 EPS for the current fiscal year and $-3.27 EPS for the next fiscal year.
Shares of WAVE Life Sciences Ltd. (WVE) opened at 20.10 on Monday. The stock’s 50 day moving average is $19.11 and its 200 day moving average is $23.57. WAVE Life Sciences Ltd. has a 52-week low of $15.15 and a 52-week high of $40.15. The stock’s market capitalization is $557.11 million.
In other WAVE Life Sciences news, insider Michael A. Panzara sold 7,414 shares of the firm’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $16.67, for a total transaction of $123,591.38. Following the completion of the transaction, the insider now directly owns 15,336 shares of the company’s stock, valued at approximately $255,651.12. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 53.00% of the stock is owned by company insiders.
A number of equities research analysts recently weighed in on WVE shares. Jefferies Group LLC set a $42.00 price target on shares of WAVE Life Sciences and gave the company a “buy” rating in a report on Thursday, June 8th. JMP Securities reissued an “outperform” rating and set a $40.00 price objective on shares of WAVE Life Sciences in a report on Friday, June 9th. Zacks Investment Research lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, ValuEngine lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Friday, June 16th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $42.00.
About WAVE Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.